Q2:19 Healthcare Deal Value, Services vs. Technology
Healthcare deal value in the second quarter totaled $138.7 billion, a slight 7% decrease from the first quarter’s $149.0 billion. Both quarters in 2019 featured a single, mega-billion-dollar deal—the $74 billion Bristol-Myers Squibb/Celgene deal in Q1 and the $87 billion AbbVie/Allergan hook-up in Q2—while the second quarter of 2018 included Takeda’s $81.5 billion deal for Shire plc. The graph below seems to indicate something terribly wrong happened in the second half of 2018, but the spending totals of those two quarters are more typical than the $100-billion-plus quarters that began in Q4:17. Economic uncertainty is still very present in mid-2019 and could grow into a recession at some... Read More »
Q2:19 Healthcare Deal Volume, Services vs. Technology Sectors
With 431 deals announced in the second quarter, acquisition activity was 9% higher than the 394 transactions announced in the previous quarter. Year over year, however, deal volume was 11% lower than the same quarter in 2018, which had 484 deals. The first quarter of 2019 was the slowest of the previous four quarters, at 394 deals. Happily, the second quarter’s activity picked up, as many deal makers predicted it would. Still, talk of recession has grown more insistent, with deal makers predicting an economic slowdown within 12 months to two years. The urgency to complete deals in 2019 has likely fueled some of the activity we’re seeing this year. Deal volume in the health care services... Read More »
Health Care M&A Deals, Week Ending July 26, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Ligand Pharmaceuticals Incorporated Ab Initio Biotherapeutics $12,000,000 Zambon S.p.A. Breath Therapeutics GmbH $156,190,000 eHealth Acquirer Target Price BioTelemetry, Inc. ADEA Medical AB N/A Hospitals Acquirer Target Price Medical... Read More »
Health Care M&A Deals, Week Ending July 19, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Boehringer Ingelheim AMAL Therapeutics N/A AbbVie Inc. Mavupharma N/A Interpace Diagnostics Group, Inc. Biopharma services business $23,500,000 LifeSpan BioSciences Everest Biotech Ltd. N/A Astellas Pharma Inc. Exclusive license to FX-322 $80,000,000 Gilead... Read More »
Health Care M&A Deals, Week Ending July 12, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Jazz Pharmaceuticals plc Preclinical Pan-RAF inhibitor program $3,500,000 Altimmune Inc. Spitfire Pharma, Inc. $5,000,000 eHealth Acquirer Target Price iMedX, Inc. Prevalent, Inc. and Axcension, Inc. N/A Waystar Digitize.AI N/A Rhapsody... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
